Hennion & Walsh Asset Management’s Seres Therapeutics MCRB Stock Holding History

Hennion & Walsh Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,055	Closed	-$346K	–	824
2023 Q1	$346K	Sell	3,055 -104	-3%	-$11.3K	0.02%	600
2022 Q4	$354K	Buy	3,159 +399	+14%	+$53.5K	0.02%	582
2022 Q3	$354K	Sell	2,760 -38	-1%	-$3.89K	0.02%	560
2022 Q2	$192K	Sell	2,798 -42	-1%	-$3.62K	0.01%	726
2022 Q1	$404K	Buy	2,840 +58	+2%	+$8.92K	0.02%	563
2021 Q4	$463K	Buy	2,782 +174	+7%	+$27.6K	0.02%	550
2021 Q3	$363K	Buy	2,608 +893	+52%	+$175K	0.02%	589
2021 Q2	$818K	Buy	+1,715	New	+$724K	0.04%	406

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Hennion & Walsh Asset Management's MCRB Position: Q2 2023 in Review

Hennion & Walsh Asset Management sold out of Seres Therapeutics (MCRB) in Q2 2023, closing a stake of 3,055 shares — an estimated $346K sold.

Hennion & Walsh Asset Management first reported a position in MCRB in Q2 2021 and held it in 8 quarters. The position peaked at $818K in Q2 2021. 137 funds tracked by Wall St. Rank hold MCRB as of Q2 2023.

Hennion & Walsh Asset Management reported no remaining Seres Therapeutics position as of Q2 2023 after selling out during the quarter.
Hennion & Walsh Asset Management sold 3,055 Seres Therapeutics shares in Q2 2023, an estimated $346K.
Hennion & Walsh Asset Management first reported a position in Seres Therapeutics in Q2 2021 and held it in 8 quarters.
Hennion & Walsh Asset Management's Seres Therapeutics position peaked at $818K in Q2 2021.
137 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.